Verition Fund Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.0% in the third ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

过去十余年，BTK抑制剂市场持续爆发。自伊布替尼在2013年获批用于治疗慢性淋巴细胞白血病以来，BTK抑制剂高歌猛进，几乎称霸血液瘤领域，市场规模也已超百亿美元。当然，随着越来越多的入局者，BTK抑制剂市场也变得暗流涌动起来。伊布替尼走上下坡路，Calquence、泽布替尼以及Pirtobrutinib等新生代力量走上坡路，未来还会 ...

Dec. 5, 2024 — Mangroves have been shown to provide $855 billion in flood protection services worldwide, according to a new ... Dec. 4, 2024 — Coconut palms are king throughout the tropics ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

European stock markets closed mixed in Monday trading as the Stoxx Europe was up 0.14%, Germany's DAX was off 0.19%, the FTSE in London gained 0.52%, France's CAC rose 0.72%, and the Swiss Market ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a ...